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Abstract
We investigated the effects of deferoxamine on the differentiation of embryonal carcinoma F9 cells. Deferoxamine, a
widely used therapeutic agent for thalassemia and iron overload, was found to induce F9 cell differentiation and to have
some unique characteristics compared with other chelators, hinokitiol and dithizone, which were previously reported to
induce differentiation of these cells. This hydrophilic agent induced reversible differentiation as did sodium butyrate,
whereas other chelators did not. However, morphological features of the cells after deferoxamine-induced differentiation
were similar to those of cells incubated with the other chelators. The differentiation-inducing activity of deferoxamine was
abolished by preincubation with Fe3q ions, similarly to the other chelators examined. Moreover, cell proliferation was
inhibited by treatment with this agent, and the numbers of cells in the colonies were reduced by apoptosis. Based on these
results, we conclude that deferoxamine induces differentiation and apoptosis of F9 cells via chelation of extracellular
andror intracellular Fe3q ions.
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1. Introduction
Mouse F9 cells, teratocarcinoma-derived embry-
w xonal carcinoma cells cloned by Bernstein 1 , are
pluripotent cells with a very low rate of spontaneous
differentiation. These cells have been reported to
differentiate into embryonic endoderm cells follow-
ing treatment with retinoic acid, sodium butyrate,
antibiotics and potent iron chelators such as hinoki-
) Corresponding author. Fax: q81 6 879 8234; E-mail: k-
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w xtiol and dithizone 2–6 . The phenotypes of differen-
tiated and undifferentiated F9 cells are different both
morphologically and biochemically. For example, cell
shape changes from spherical to polygonal with dif-
w xferentiation 2 , and differentiated cells express extra-
cellular matrix proteins such as plasminogen activator
 . w xPA , type IV collagen and laminin 7 accompanied
by reduction in the level of expression of stage
w xspecific embryonic antigen-1 8 . Moreover, it was
recently reported that the transcription of several
genes is activated during the differentiation process
w xin F9 cells 9–11 . These changes are very similar to
those occurring in the early stages of normal embryo-
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genesis, and thus they are a good model for studying
both embryogenesis and mechanisms of differentia-
w xtion 12 .
We reported previously that the potent iron chela-
tors tropolone, hinokitiol and dithizone induced the
w xdifferentiation of F9 cells 5,6 , and suggested that
their abilities to chelate iron ions might be responsi-
ble for their biological activity. To clarify the mecha-
nism of induction by chelators, we further investi-
gated the differentiation-inducing activity of deferox-
amine, an iron chelator used therapeutically. This
agent was originally obtained from Streptomyces pi-
w xlosus by Koberle in 1964 13 and it has been re-
ported to bind to an equimolar amount of ferric ion to
w xform a stable complex 14 . Although deferoxamine
can bind other metal ions such as copper, cobalt and
zinc, its binding to ferric ion is the most stable. The
affinity of deferoxamine to iron ions is higher than
those of other chelators, e.g. ethylenediamine te-
 .traacetic acid EDTA and diethylenetriamine pen-
w xtaacetic acid 15 . Thus, deferoxamine has been
widely used clinically in treatment of thalassemia and
w xiron overload 15–18 . Deferoxamine was reported to
block the cell cycle reversibly at the G1-S border
w x19 . It was also suggested that deferoxamine is an
effective agent for cancer therapy, especially for
treatment of neuroblastoma, because it is an inhibitor
w xof DNA synthesis 20–22 . In a study using the
human leukemia cell lines K562 and Daudi cells, the
inhibition of DNA synthesis by this agent was shown
to be due to its ability to block ribonucleotide reduc-
tase which participates in the synthesis of deoxyribo-
w xnucleotides 23 .
We found that deferoxamine has differentiation-
and apoptosis-inducing activities in F9 cells, and also
assessed its unique induction mechanism as com-
pared with those of other chelators.
2. Materials and methods
2.1. Materials
Deferoxamine was purchased in mesylated form
 .from Sigma Chemical Co. St. Louis, MO, USA .
Dithizone and ferric chloride were from Nacalai
 .Tesque Kyoto, Japan . DNA 100 bp ladder marker
 .was from Pharmacia Biotech Piscataway, NH, USA .
All other reagents used were of analytical grade.
2.2. Cell culture
F9 cells were provided by Dr. Yoshitake
Nishimune Research Institute for Microbial Dis-
.eases, Osaka University . Stock cultures of F9 cells
were grown on tissue culture-grade dishes Iwaki
.Glass, Japan in Eagle’s minimum essential medium
 .MEM, Nissui Pharmaceutical Co., Tokyo, Japan
supplemented with 10% fetal bovine serum Life
.Tech, Gaithersburg, MD, USA , 5 mM L-glutamine
and 1 mM sodium pyruvate at 378C in a humidified
atmosphere of 5% CO -air. For experimental cultiva-2
tion, the cells in stock cultures were detached from
the surface of dishes by 0.2% trypsin-0.02% EDTA
 .in phosphate buffered saline PBS at 378C for 5 min,
washed, and resuspended in MEM. Then, the cells
were seeded at an appropriate cell density in dishes.
2.3. Assay of PA production
The assay method for determining PA-producing
w xcolonies was described elsewhere 24,25 . Briefly,
cells were seeded at about 120 cells per 35 mm
 .gelatin-coated dish Nunclon, Denmark and cultured
for 3.5 days to allow proliferation and colonization.
Then, the culture medium was changed to fresh
MEM containing chelators. After treatment, colonies
were counted macroscopically, washed with PBS and
 .further incubated with 1 ml of prewarmed 438C
agar-overlay solution containing 0.75% agar, 2.5%
 .skimmed milk Difco, Detroit, MI, USA and 0.28
CU bovine plasminogen Daiichi Pure Chemicals
.Co., Japan in MEM. The numbers of PA-producing
colonies were estimated by counting clear ca-
seinolytic zones in the opaque layer. PA production
rate was calculated for the percentage of the number
of plaques relative to the total number of colonies in
each dish.
2.4. Assay of cell proliferation
Cell proliferation was assayed by counting the
 5.numbers of cells. F9 cells 1=10 suspended in
MEM were seeded into 6 cm dishes. After 48 h
cultivation, medium was changed to fresh MEM con-
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taining deferoxamine, and the cells were cultured for
further 24 h. The number of cells was counted using
a hematocytometer after detachment by trypsin-EDTA
at the indicated times.
2.5. Detection of DNA fragmentation
Detection of DNA fragmentation as an indicator of
apoptosis was performed by the method described by
w xRamachandra and Studzinski 26 . Briefly, total DNAs
from deferoxamine-treated and non-treated cells were
electrophoresed in 2% agarose gels, stained with
ethidium bromide, and visualized on a UV transillu-
minator.
3. Results
3.1. Differentiation-inducing acti˝ity of deferoxamine
As shown in Fig. 1A, colonized F9 cells were
treated at various concentrations of deferoxamine for
24 h. PA production rate, which indicates the per-
centage of differentiated colonies, was increased by
this treatment in a dose-dependent manner. Maximum
activity was observed at the concentration of 100
 .mgrml 152 mM , and most of the colonies were
differentiated at this concentration. At 5.0 mgrml
 .7.6 mM , however, deferoxamine did not induce
differentiation of F9 cells. This activity was compara-
 . w xble to that of hinokitiol at 10 mgrml 60.9 mM 5 .
The production rate of PA was also dependent on the
 .duration of treatment Fig. 1B . A marked increase in
PA production was observed after treatment with
 .deferoxamine 100 mgrml for 8 h, and further
enhancement was observed up to 24 h in a time-de-
pendent manner.
3.2. Morphological changes
After 24 h treatment of F9 cells with deferoxamine
at 100 mgrml, the cells changed to a polygonal
 .shape typical of differentiated F9 cells Fig. 2B
w x2,5 . The morphology of F9 cells treated with defer-
oxamine for 24 h was markedly different from that of
 .undifferentiated control cells Fig. 2A .
Fig. 1. Effects of deferoxamine on PA production in F9 cells. PA
 .production rate % was estimated by the agar-overlay method in
 .which the formation of caseinolytic plaques was detected. A
Dose-response curve of deferoxamine on PA production. F9
colonies were treated with various concentrations of deferoxam-
 .ine for 24 h. B Time-course of PA production. F9 colonies were
treated with 100 mgrml deferoxamine for the indicated times.
All data represent means"S.D. of triplicate cultures.
3.3. Inhibitory effect of metal ions on deferoxamine-
induced differentiation of F9 cells
We previously reported that differentiation-induc-
ing activities of the chelators, tropolone, hinokitiol,
and dithizone, were diminished by treatment with
3q w xFe ions prior to addition to cultures of F9 cells 6 .
To assess the role of iron chelation in deferoxamine-
induced differentiation, we investigated the effect of
3q  .preincubation with Fe ions Fig. 3 . Pretreatment
 .of 50 mgrml 76 mM deferoxamine with 40 mM
and 60 mM Fe3q decreased PA production rates of
F9 cells to 76.4% and 41.8%, respectively, of those
of non-pretreated deferoxamine-treated cells. Preincu-
bation with more than 80 mM Fe3q blocked the
ability of deferoxamine to induce differentiation of
F9 cells.
3.4. Re˝ersibility of differentiation of F9 cells by
deferoxamine
It was reported that the differentiation of F9 cells
treated with retinoic acid and hinokitiol was irre-
w xversible 5,27 , while differentiation with sodium bu-
w xtyrate was reversible 25 . We investigated the re-
versibility of differentiation in cells treated with de-
 .feroxamine and dithizone Fig. 4 . The colonized F9
cells were differentiated by treatment with 100
mgrml deferoxamine and 10 mgrml dithizone for 24
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 .Fig. 2. Morphological changes of F9 cells treated with deferoxamine. F9 cells were plated on gelatin-coated dishes and treated with B or
 .  .without A deferoxamine 100 mgrml for 24 h. Bar, 50 mm.
h. Then, the medium was changed to fresh MEM and
culture was continued for the indicated periods. PA
production rates of cells treated with dithizone were
constant throughout the experimental period, whereas
that induced by deferoxamine began to disappear at
12 h and reached control level after 24 h cultivation
in MEM. Therefore, in view of the reversibility, the
mechanism of F9 differentiation by deferoxamine
may be different from those of other chelators.
Fig. 3. Inhibition by Fe3q of deferoxamine-induced PA produc-
tion in F9 cells. The indicated concentrations of Fe3q were
 .preincubated with 50 mgrml 76 mM deferoxamine for 30 min
at 378C in the culture medium. F9 colonies were then exposed to
the medium for 24 h and their PA production rates were assayed.
yDFX indicates control culture without deferoxamine and Fe3q.
Values are means"S.D. of triplicate cultures.
3.5. Cell proliferation and DNA fragmentation
As shown in Fig. 2, the number of cells was
decreased in colonies treated with deferoxamine. To
confirm this quantitatively, the number of cells was
Fig. 4. Reversibility of differentiation induced by deferoxamine.
 .F9 colonies were treated with 100 mgrml deferoxamine v or
 .10 mgrml dithizone ‘ for 24 h. After washing, the cells were
incubated without chelators for the indicated times. Then, PA
production rate was assessed by the agar-overlay method. yin-
ducer indicates control culture without chelators. All values
represent means"S.D. of triplicate cultures.
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Fig. 5. Effects of deferoxamine on cell proliferation. F9 cells
 5.1=10 were seeded into 6 cm dishes and cultured for 48 h.
 .Then, culture medium was changed to fresh medium with v or
 .without ‘ 100 mgrml deferoxamine. The number of cells was
counted at the indicated times using a hematocytometer. Values
are means"S.D. of triplicate assays.
compared following cultivation in the presence or
absence of deferoxamine. When F9 cells proliferated
exponentially at 48 h after seeding, the medium was
Fig. 6. Detection of DNA fragmentation in deferoxamine-treated
F9 cells. Aliquots of 70 mg of DNA from deferoxamine 100
.  .  .mgrml -treated lane 3 and non-treated lane 2 cells were
electrophoresed in 2% agarose gels, and stained with ethidium
bromide. Lane 1 is 100 bp ladder marker.
changed to fresh medium containing deferoxamine.
Cells cultured without deferoxamine continued to
grow over the experimental period, whereas deferox-
amine inhibited the growth at 8 h after treatment and
 .markedly reduced the cell number after 24 h Fig. 5 .
Further analysis revealed that the reduction of cell
number was in part associated with the occurrence of
apoptotic cell death. Total DNAs obtained from con-
trol and deferoxamine-treated F9 cells were elec-
 .trophoresed in 2% agarose gels Fig. 6 . DNA ladder
formation was observed in samples from deferoxam-
ine-treated cells, with fragmented DNA in multiples
of 170–180 base pairs which is typical of apoptosis.
No signs of DNA fragmentation were observed in
samples from control cells.
4. Discussion
Deferoxamine has been widely used for the treat-
ment of various diseases such as thalassemia, iron
w xoverload, rheumatoid arthritis, and malaria 15–18 .
It was reported that deferoxamine induced the differ-
entiation of human leukemic cell line HL-60 to
w xmonocyte-macrophage cells 28,29 . However, other
groups reported that deferoxamine did not induce
w xdifferentiation of HL-60 cells 30,31 . Thus, the dif-
ferentiation-inducing activity of deferoxamine in HL-
60 cells is controversial. However, in this study, we
observed differentiation-inducing activity of deferox-
amine in F9 cells. These cells underwent a morpho-
logical change to the typically differentiated polygo-
nal shape following treatment with deferoxamine Fig.
.2 , which was quite similar to that induced by hinoki-
tiol. Moreover, the differentiation-inducing activity of
deferoxamine was dose- and time-dependent simi-
larly to that of hinokitiol, and this agent acted more
rapidly than retinoic acid again similarly to other
chelators.
Previously, we reported that differentiation-induc-
ing activity of chelators was specifically inhibited by
preincubation with Fe3q ions before addition to cell
w xcultures 6 . The activity of deferoxamine was also
dose-dependently inhibited by preincubation with
3q  .Fe Fig. 3 . It has been reported that deferoxamine
3q w xbinds equimolar amounts of Fe 14 . Thus, defer-
oxamine may stoichiometrically chelate Fe3q to form
an inactive complex, and the remaining deferoxamine
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functions to induce the differentiation of F9 cells. We
speculate that the chelating ability of this agent causes
the removal of extracellular andror intracellular
functional Fe3q, resulting in F9 cell differentiation.
In fact, it has been reported that deferoxamine re-
duces the intracellular iron level of some cell lines
w x29,32 . Iron ions in biological systems are always
bound to proteinaceous ligands and are never present
w xin free form 33 . About 60 and 30% of total iron ions
w xbind to hemoglobin and ferritin, respectively 15 .
There are many other proteins which contain iron
 .ions 20 protein species or more such as ribonu-
cleotide reductase, transferrin and cytochromes
w x15,33 . We speculate that the main target of deferox-
amine may be ribonucleotide reductase in F9 cells
w xsimilarly to HL-60 cells 28,34 although we have no
direct evidence to support this hypothesis, because it
was reported that some chelators including deferox-
amine inhibited the activity of this enzyme in many
cell lines through the removal of iron ion from its
w xactive center 35–38 . Furthermore, our speculation
seems reasonable due to both the participation of
w xribonucleotide reductase in DNA synthesis 39,40
and the inhibition of DNA synthesis in F9 cells
w xinduced to differentiate by various chelators 5 .
The similarity of F9 cells differentiated by treat-
ment with deferoxamine and other chelators sug-
gested that the differentiation-inducing mechanisms
of these agents may be the same. However, only
those cells differentiated by deferoxamine showed a
reversible change after its removal from the culture
medium. The only other compound capable of induc-
ing reversible differentiation of F9 cells reported to
w xdate is sodium butyrate 25 . The duration required
for dedifferentiation was longer in cells differentiated
by deferoxamine than by sodium butyrate. This re-
versibility may have originated from the character-
istics of deferoxamine which acts as a reversible
w xS-phase inhibitor 19 . Since deferoxamine is a hy-
drophilic chelator, it is also possible that the kinetics
of deferoxamine in culture are different from those of
other hydrophobic chelators.
It has also been reported that deferoxamine has
cytotoxic and antiproliferative effects on many cell
w xlines 20,41–43 . In this study, deferoxamine inhib-
 .ited the proliferation of F9 cells Fig. 5 . Some
investigators reported that deferoxamine induced
w xapoptosis in HL-60 and K562 cells 28,44 , and Haq
et al. reported that the iron depletion caused apoptosis
w xin CCRF-CEM cells 45 . The apoptosis induced by
deferoxamine in F9 cells is thought to be the result of
iron starvation by chelation. However, the relation-
ships between differentiation and apoptosis remains
to be clarified. In addition, it has been reported that
iron ions significantly participate in radical produc-
w xtion 46,47 and that there are iron-responsive ele-
w xments in some mRNA sequences 48–50 . Therefore,
it is likely that iron chelators added to cultures alter
the levels of radicals andror the regulation of gene
expression in cells, resulting in cell differentiation
and apoptosis. The mechanisms of induction of dif-
ferentiation and apoptosis in F9 cells should be inves-
tigated in more detail to gain further insight into
normal development and to develop novel agents for
cancer chemotherapy.
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